image description

Tag: belimumab

How Are the New Lupus Nephritis Guidelines Impacting Treatment?

Recognized as National Kidney Month, March is the ideal time to learn more about the 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Recently issued, the guidelines are designed to provide healthcare providers with up-to-date guidance on the care and treatment of adults and children with lupus […] Read More

Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting

November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] Read More

Promising New Lupus Treatments Highlighted ACR Annual Meeting

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More

New Data Showed Safety and Effectiveness of Benlysta for Kids

July 27, 2020 A new international study published in Annals of the Rheumatic Diseases showed that belimumab (Benlysta) was safe and effective when given intravenously to children. In this Phase 2, randomized, placebo-controlled, blinded study, 93 patients 5-17 years of age received standard therapy plus either placebo or belimumab. As measured by commonly used tools, […] Read More

Promising News from Major Medical Meeting, EULAR

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […] Read More

Research Shows Benefit to Starting Belimumab Sooner Rather Than Later

April 16, 2020 Treating people with lupus earlier with belimumab (Benlysta) may work better than as a last option according to a study just published in the well-respected journal Arthritis & Rheumatology  Researchers in Italy analyzed data from 466 people with lupus at 24 centers in Italy who were receiving belimumab intravenously.  They looked at […] Read More

LRA Shares Excitement For What’s Ahead in Lupus Nephritis

January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […] Read More

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […] Read More